Kura Oncology Inc. (KURA)
The price, the headline numbers and the latest news, in one place.
Kura Oncology Inc. (KURA) Stock Price, Analysis & Data
| Bid | 12.65 |
| Market Cap | 1.13B |
| Revenue (ttm) | 77.22M |
| Net Income (ttm) | -296.78M |
| 0.38 | |
| -3.24 | |
| n/a | |
| -5.62 | |
| P/B (ttm) | 23.27 |
| P/S (ttm) | 14.58 |
| Earnings Date | Nov 3, 2026 |
| Ask | 16.32 |
| Volume | 1,805,273 |
| Avg. Volume (20D) | 1,843,160 |
| Open | 13.05 |
| Previous Close | 13.18 |
| Day's Range | 12.62 - 13.17 |
| 52-Week Range | 7.36 - 13.90 |
| Analyst | Strong Buy |
| Price Target | 28 (121.17%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a...
Financial Performance
In 2025, Kura Oncology's revenue was 67.48M, an increase of 25.24% compared to the previous year's 53.88M. Earnings were -278.67M, an increase of 60.17%.
Financial StatementsAnalyst Forecast
According to 12 analyst ratings, the average rating for KURA stock is "Strong Buy". The 12-month stock price forecast is 28, which is upside of 121.17% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $18.27M misses estimates by $0, with 29.47% YoY growth.
- EPS of -0.77 exceeds estimates by 0.11, with -16.67% YoY decline.
Analysts project revenue of ... Upgrade
